EARN25

Biotech Could Burst Higher, Says Signal

A short squeeze could fuel more upside for ACAD too

Digital Content Manager
Jun 29, 2020 at 3:50 PM
facebook X logo linkedin


The shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have been trading in a channel of higher highs lately, contained by the $45 and $50 levels during the past three months. The stock has made several attempts to topple this upper level, with its last attempt putting it at a record high of $53.75, before a swift pivot back down the charts. This most recent pullback, however, put the security face-to-face with a historically bullish trendline that, if past is precedent, could sent ACAD back in the direction of its record highs. 

Specifically, the biotech pulled back to its 80-day moving average after a length period north of the trendline. According to a study from Schaeffer's Senior Quantitative Analyst Rocky White, the security has come within one standard deviation of this trendline five other times in the past three years. ACAD was higher one month later after four of these signals, and averaged a one-month return of 3.4%. A similar move from its current perch of $48.32 would put the security right back below the $50 mark. 

Short interest is starting to unravel, down 0.2% in the last two reporting periods, though there's still plenty of room for a short squeeze to propel the stock higher. The 11.49 million shares sold short make up nearly 8% of ACAD's available float and would take almost two weeks to cover at the equity's average daily pace of trading. 

For those wanting to speculate on ACAD's next move, options look like a prudent play right now. ACADIA's Schaeffer's Volatility Index (SVI) of 64% stands higher than just 21% of readings from the past year. This means options players are pricing in relatively low volatility expectations at the moment.  

 

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!